Psychedelic Medicine - Jan 18, 2026
Back to Stakeholders
Categories
1 domain / 2 areas / 1 specialization
University of Washington
Data updated
United States
6 Trials2 Papers
At UW, researchers are working on clinical trials with psilocybin (provided by Usona). Dr Anthony Back, co-director of the University's Center for Excellence in Palliative Care, led a trial exploring the effects of psilocybin to alleviate the mental health burden inflicted on frontline healthcare workers throughout the COVID-19 pandemic. As Seattle became the largest city in the US to decriminalise psilocybin mushrooms in October 2021, and with ongoing legislative efforts at the state level, more research with psychedelics is anticipated and occurring at UW.
Academic Research
2 papersPublished Papers
2
Trial Involvement
6
Distinct Focus Topics
0
Latest Publication
Jan 18, 2026
Recent Papers
Quick Facts
- Type
- academic
- HQ
- United States
- Website
- Visit
Research Landscape
What the 6 registered trials University of Washington sponsors or participates in look like when you line them up. Counts come from Blossom’s trial records as of July 2026.
What's live right now, and what stopped?
SourcedRegistry status of all 6 University of Washington trials Blossom tracks. Orange marks trials recruiting or opening.
Don't read stopped trials as failures: trials end early for funding, recruitment, and strategy reasons too. Status is as last synced from the registry; some 'recruiting' trials may already have finished.